Clinical Trial Update: Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older [Phase 3]

View source ↗

Summary

Phase 3 safety and immunogenicity update of REPEVAX followed by REVAXIS in adults 40+ years.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• REPEVAX
• Revaxis (Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus Vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Diphtheria, Tetanus | Phase 3 | Status: COMPLETED